Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAZ954 alone and in combination in advanced solid tumors
NCT04237649Phase 1Terminated
- Sponsor
- Novartis
- Start
- Feb 2020
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of kaz954 in solid tumor (advanced stage) (4 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 35 days, Adverse Events at 52 weeks and 2 more. Started Feb 2020; status: terminated.
02
Drugs
kaz954
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04237649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04237649.